Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-2 adjuvant durvalumab with or without bevacizumab in high-risk hepatocellular carcinoma
2023-507689-26-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Durvalumab + bevacizumab, Durvalumab monotherapy and Placebo control (3 arms). Primary endpoint: Recurrence-free survival. Planned start Oct 2019; status: authorised.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-507689-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507689-26-00.